<DOC>
	<DOCNO>NCT01444248</DOCNO>
	<brief_summary>The study design trial open-label , randomize , multi-center , parallel-group study .</brief_summary>
	<brief_title>Compare Compliance Patients Treated With Once-daily ( od ) Twice-daily ( Bid ) Glimepiride Metformin Fixed Combination Therapy</brief_title>
	<detailed_description>The effectiveness treatment disease depend mainly two factor : efficacy treatment compliance patient treatment . Polymedication one predispose factor low compliance type 2 DM . It expect simple regimen may improve compliance . Amaryl Mex phase III trial design compare compliance patient different dose regimen oral antidiabetic drug . However , find patient ' compliance morning well evening , suggest Amaryl Mex daily regimen may improve compliance . Pill count gold standard measure compliance , method provide incomplete unreliable result . Advanced electronic monitoring device obtains detail patient ' behavior day long period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients age 18 ~ 75 year screen Patients diagnose type 2 DM least 3 month Patients treat stable dose combination therapy glimepiride 4mg metformin 1000mg switch Amaryl M 2/500mg bid Amaryl Mex 2/500mg 2T od regimen . HbA1c ≤ 9 % randomization BMI ≤ 40 kg/m2 randomization Patients would give informed consent Patients perform SMBG record data patient 's diary Patients understand use MEMS properly Patients medical history acute metabolic complication diabetic ketoacidosis , hyperosmolar nonketotic coma within 3 month prior study participation Patients insulin therapy randomization Patients receive systemic corticosteroid agent within 4 week prior study participation Patients acute , severe cardiovascular disease ( e.g. , heart failure , myocardial infarction , stroke , etc ) . Pregnant lactating female history drug alcohol abuse Patients know hypersensitivity ingredient study drug drug sulfonylurea , sulfonamide , biguanide class Nightshift worker Patients experience participate clinical trial within 3 month prior study participation Clinically significant laboratory abnormality screen labs medical condition would affect completion outcome study base investigator 's decision Patients serum creatinine level &gt; 1.5 mg/dl male &gt; 1.4 mg/dl female Patients ALT AST &gt; 3x ULN Any condition require help others drug administration ( e.g . manual disability , serious visual defect , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Amaryl MEX</keyword>
</DOC>